Mesoblast Unveils Path to Bring Its Key Products to Market

NEW YORK and MELBOURNE, Australia, Aug. 25, 2014 -- Regenerative medicine company Mesoblast Limited today reported 2014 financial results and unveiled its strategy to prioritize and bring to market clinically differentiated products based on its proprietary Mesenchymal Precursor or Stem Cell technologies.

http://ift.tt/1mKzgg1